The Hunterbrook report, which followed a five-month investigation, claims that Ensign Group prioritized executive payouts over patient safety. The findings suggest a business model built on inadequate care and the redirection of taxpayer funding to corporate affiliates. These allegations have prompted Rosen Law Firm to initiate a formal probe into potential securities claims on behalf of shareholders who may have suffered losses due to allegedly misleading business information provided by the firm.

Investors who held Ensign Group securities during the period in question are now being invited to join a prospective class action. Rosen Law Firm, which asserts a history of high-stakes litigation, is handling the case on a contingency fee basis. Shareholders seeking further details regarding the investigation or legal representation are directed to the firm’s website or the office of attorney Phillip Kim.